Welcome to our dedicated page for FILANA THERAPEUTICS SEC filings (Ticker: FLNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FILANA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FILANA THERAPEUTICS's regulatory disclosures and financial reporting.
Filana Therapeutics, Inc., a clinical‑stage CNS biotech, reported a net loss of $8.6 million for Q2 2026 and $18.9 million for the six months ended June 30, 2026, lower than the prior‑year periods as research and development and general and administrative expenses declined.
Cash and cash equivalents were $82.7 million at June 30, 2026, with total assets of $103.9 million and stockholders’ equity of $63.6 million; management believes current working capital will meet needs for at least the next 12 months. The company has no product revenue and an accumulated deficit of $515.0 million.
Development is centered on lead candidate simufilam for TSC‑related epilepsy, but the related IND is on full clinical hold pending additional data and protocol changes. Legal matters remain significant, including a previously paid $40 million SEC civil penalty and a proposed $31.25 million securities class‑action settlement that has been accrued and funded into escrow, contributing to $32.75 million of litigation reserves.
Filana Therapeutics, Inc. reported second quarter 2026 results and a business update focused on its simufilam program for TSC-related epilepsy. The company continues to work with the FDA to address information requests related to the full clinical hold on its proof-of-concept trial and is maintaining engagement with the TSC community, including sponsoring the 2026 TSC World Conference.
Cash and cash equivalents were $82.7 million at June 30, 2026, with no debt, and net cash used in operations in the first half of 2026 was $12.7 million, described as below prior guidance. R&D expense for the quarter was $3.3 million and G&A expense was $6.1 million, both lower than the prior year due to the completed phase-out of the Alzheimer’s disease program and the absence of a $31.25 million securities litigation loss contingency recorded in 2025.
Net loss for the quarter was $8.6 million, or $0.18 per share, compared with a net loss of $44.2 million, or $0.92 per share, a year earlier. On July 23, 2026, Filana funded $31.25 million into escrow toward potential settlement of certain securities litigation; this cash will remain restricted. The company projects second-half 2026 operating cash use of $11 to $15 million plus the litigation funding and estimates unrestricted year-end 2026 cash of $36 to $40 million. Shares outstanding were 48.3 million as of July 27, 2026.
Filana Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where a quorum was reached with 24,559,776 shares present out of 48,307,896 entitled to vote, or approximately 51%.
Stockholders elected three directors to three-year terms, approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, and ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. They also approved 2025 executive compensation in a non-binding advisory vote, confirming the company’s pay practices while maintaining the existing board and governance structure.
Filana Therapeutics, Inc. reported a Q1 2026 net loss of $10.3 million, improving from $23.4 million a year earlier, as research and development spending fell to $4.5 million from $13.7 million after discontinuing its Alzheimer’s program. Cash and cash equivalents were $86.6 million and total stockholders’ equity was $68.1 million as of March 31, 2026. The company carries an accumulated deficit of $506.4 million and has reserved $32.75 million for litigation-related contingencies, including $31.25 million tied to a proposed securities class action settlement. Management believes existing working capital will fund operations for at least the next 12 months while it focuses on developing simufilam for TSC‑related epilepsy under an FDA clinical hold.
Filana Therapeutics reported Q1 2026 results showing sharply lower expenses and a smaller loss as it pivots to TSC-related epilepsy. Net loss was $10.3 million, or $0.21 per share, versus $23.4 million, or $0.48, a year earlier.
Research and development spending fell to $4.5 million from $13.7 million, a 67% decrease driven by phasing out the Alzheimer’s program. General and administrative costs declined to $6.6 million from $10.9 million, partly because a $3.0 million legal loss contingency booked in Q1 2025 did not recur.
Cash and cash equivalents were $86.6 million at March 31, 2026, with no debt, and the company estimates cash at June 30, 2026 in a range of $47–$50 million. Guidance includes net cash used in operations of $14–$17 million for first-half 2026 plus an expected $31.25 million loss contingency payment related to potential settlement of certain securities litigation.
Filana Therapeutics, Inc. is asking stockholders to approve several items at its 2026 virtual annual meeting on June 11, 2026. Stockholders will vote on electing three Class II directors, amending the 2018 Omnibus Incentive Plan, ratifying Ernst & Young LLP as auditor for 2026, and a non-binding advisory vote on 2025 executive compensation.
The equity plan amendment would raise authorized shares from 5,000,000 to 9,000,000, extend the plan’s term to January 31, 2030, tighten annual limits for individual and non‑employee director awards, and add governance features such as an explicit ban on option repricing and a reference to the Dodd-Frank clawback policy. As of April 21, 2026, Filana had 48,307,896 common shares outstanding, and the company estimates total potential dilution from equity plans at about 7.6% if the increase is approved.
Filana Therapeutics, Inc. reported that board member Michael O’Donnell has decided to resign from its Board of Directors, effective at the conclusion of the Company’s 2026 annual meeting of stockholders. He will continue to serve as a director until that meeting is completed.
The Company stated that Mr. O’Donnell’s resignation is not due to any disagreement with Filana Therapeutics, its management, or the Board regarding operations, policies, or practices. The report was signed on behalf of the Company by Chief Financial Officer Eric J. Schoen.